• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Natco Pharma gets USFDA approval for lenalidomide capsules

expresspharmaMay 24, 2021

Tag: NATCO , FDA , lenalidomide capsules

Natco Pharma has received final approval of its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, 5 mg, 10 mg, 15 mg, and 25 mg strengths, from the US Food and Drug Administration (FDA), and tentative approval for the 2.5 mg and 20 mg strengths.

Natco Pharma gets USFDA approval for lenalidomide capsules

NATCO, along with its marketing partner Arrow International (a US affiliate of Teva Pharmaceutical Industries), previously settled the Paragraph IV litigation related to the product with Celgene (now part of Bristol-Myers Squibb), who sells the product under the brand-name REVLIMID. NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.

Previous:MSN Laboratories launches Posaconazole to treat mucormycosis

Next:COVID-19 to have long-term impact on global diabetes market: GlobalData

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Natco Pharma gets USFDA approval for lenalidomide capsules | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min
Aciclovir (FDA)

Aciclovir (FDA)
Medroxyprogesterone Acetate(FDA)

Medroxyprogesterone Acetate(FDA)
Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals

Compliance FDA 21 part 11 Packaging leak tester for pharmaceuticals
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)
Lincomycin HCL (FDA)

Lincomycin HCL (FDA)
Cilostazol(FDA Approved) (Micronized)

Cilostazol(FDA Approved) (Micronized)
Irinotecan Hcl trihudrate (FDA)

Irinotecan Hcl trihudrate (FDA)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)
Fluorfenicol( FDA)

Fluorfenicol( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service